This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension. The study included 77 hypertensive patients who were randomised at baseline to 22 months double-blind oncedaily treatment with losartan 50 mg (L group n ‫؍‬ 44 patients, mean age 54 ؎ 9 years) or hydrochlorothiazide 25 mg (HCTZ group, n ‫؍‬ 33 patients, mean age 56 ؎ 7 years). Routine haematology, blood chemistry, standard electrocardiography, echocardiography and ambulatory non-invasive 24-h blood pressure (BP) monitoring were
Introduction
The prevalence of organ damage from left ventricular hypertrophy, associated with hypertension varies from 20-80% according to population and different diagnostic criteria. [1] [2] [3] As demonstrated by the Framingham study and then confirmed elsewhere, increased left ventricular mass can be considered an independent risk factor in hypertensive patients. 4, 5 Therefore, regression of left ventricular hypertrophy was shown to be a primary pharmacologic objective.
The results of a recent meta-analysis have demonstrated the capacity of more commonly used antihypertensive drugs to reduce not only blood pressure (BP), but also that reduction of left ventricular mass is greatest with angiotensin-converting enzyme (ACE) inhibitors even though the other classes of drugs produce equivalent reduction in BP. 6 A careful evaluation of experimental design, quality of life and drug tolerability suggests that ACE inhibitors are effective and well tolerated. It also confirms the renin-angiotensin system's role in the genesis of hypertension and on left ventricular remodelling. 7, 8 However, ACE inhibition has the following limitations: activated alternative enzymatic pathways in converting angiotensin-I into angiotensin-II (eg, by the cardiac enzyme chymase), 9 and accumulation of , P = 0.38). In conclusion, losartan was well tolerated and produced a significant reduction in BP and left ventricular mass in hypertensive patients bradykinin and substance P, which are responsible for side effects like coughing and angioedema. 10, 11 The recent development of a new class of drugs, the angiotensin II antagonists, starting with losartan, able to specifically and selectively antagonise the angiotensin-II AT-I receptors 12 which are responsible for most cardiovascular effects, overcomes the limitations of ACE inhibitors without sacrificing anti-hypertensive effectiveness. [13] [14] [15] The purpose of our study was to evaluate the therapeutic efficacy, tolerability and effect of losartan on left ventricular mass after 22 months of treatment, compared to hydrochlorothiazide (HCTZ).
Materials and methods
We studied 77 patients (41 men, 36 women; age range 31-75 years), with mild-to-moderate essential hypertension. After 2 weeks of non-pharmacological therapy, all patients had a diastolic BP (DBP) between 90 mm Hg and 114 mm Hg. During this period each patient underwent a bi-weekly physical examination in the out-patient clinic with three supine BP measurements using a mercury sphygmomanometer. Patients with recent myocardial infarction or stroke, renal failure, chronic severe liver disease and congestive heart failure were excluded. All patients were in sinus rhythm and matched for body surface area. Patients provided informed consent before entering the study. After 2 weeks, in a doubleblind study, the subjects were randomly allocated to either treatment with losartan 50 mg od (L group: 44 patients, 23 men and 21 women, mean age 54 ± 9 years) or hydrochlorothiazide 25 mg od (HCTZ group: 33 patients, 18 men and 15 women, mean age 56 ± 7 years) administered in the early morning ( Table 1 ). The entire study lasted 22 months. At baseline and after 10 and 22 months, routine blood tests, standard ECG, M-mode echocardiogram and a non-invasive ambulatory BP monitoring (ABPM) were performed. The M-mode echocardiogram was performed with Acuson 3 × /p100 using 3.5 MHz phased array, placed on the III-IV left intercostal space along the parasternal line, with patients supine, in left lateral decubitous and the head of the bed kept at 30°. The end-diastolic measurements of left ventricular internal dimension, left interventricular septum and posterior wall thickness at the QRS peak using the Penn convention were measured. The left ventricular mass was calculated according to the Devereux formula. 16 Patients with a left ventricular mass index (LVMI) Ͼ130 g/m 2 in men, and Ͼ110 g/m 2 in women, based on the upper 90th percentile from 150 apparently healthy normotensive adults, were classified as having left ventricular hypertrophy. All echocardiograms were recorded on videotape. Non-invasive ambulatory BP was measured every 15 min with the oscillometric recorder SpaceLabs 90207 and repeated twice in 10 days. In cases of an arm circumference of Ͼ32 cm a broad cuff was used. The device was checked against a mercury sphygmomanometer by a Y-tube. The ABPMs with 85% or more likely readings were analysed.
The 24-h period was divided into daytime (8.00 am to 8.00 pm) and night time (8.00 pm to 8.00 am). Each diagnostic procedure had its own physician to record measurements. The acceptance of diagnostic procedures was determined using a visual analogue scale with a 10 cm line ranging from 'very annoying' on the left to 'not annoying at all' on the right, and for ABPM we included the quality of sleep and side effects. 17 We evaluated the acceptance of diagnostic procedures to exclude eventual patient withdrawal from poor compliance to diagnostic procedures. Statistical analysis was performed within-group using Student's t-test for paired data and differences between groups were compared by ANOVA with Bonferroni correction; P Ͻ 0.05 was considered statistically significant. The data are expressed as mean ± s.d.
Results
Of the 77 patients, 70 completed the study. During treatment seven patients withdrew, two in the L group of their own accord in the first week because of dizziness, and five 'non responders' in the HCTZ group in the first month ( Table 2) .
The non-invasive BP monitoring gave a 96% mean of successful readings without differences between baseline, and after 10 and 22 months of active treatment.
Both drugs significantly reduced BP, although losartan was more effective than HCTZ. In fact, a fall of 22 mm Hg and 11 mm Hg was recorded in the L group for systolic (SBP) and diastolic mean BP, respectively (P Ͻ 0.001) ( Table 3) ; in the HCTZ group the reduction was 11 mm Hg (P Ͻ 0.002) and 7 mm Hg for systolic and diastolic BP, respectively (P Ͻ 0.02) ( Table 4) . Ratio of normalisation (DBP Ͻ 90 mm Hg) or reduction of 10 mm Hg in both SBP and DBP was 72% in the L group and 52% in the HCTZ group which was already evident by the 10th month. In addition to a significant reduction in mean SBP and DBP in the 24-h monitoring, losartan was more effective than HCTZ in the last 2 h of administration (Figures 1 and 2 ). According to echocardiographic data, a considerable reduction in LVMI was observed in the L group, with significant mean changes at 10 and especially 22 months after baseline (⌬ = −11 g/m 2 , P Ͻ 0.02) ( Table 2 ); in the HCTZ group the mean changes did not achieve statistical significance (⌬ = −5 g/m 2 , P = 0.38) ( Table 4) . At the end of the study the change of the LVMI in the L group resulted from posterior wall thickness (95% confidence interval: 0.08-0.13) and interventricular septum (95% confidence interval: 0.03-0.09) reduction, whereas a left ventricular internal diameter reduction was mainly observed in the HCTZ group.
Finally, 30% of patients with left ventricular hypertrophy from the L group and 10% from the 507 HCTZ group normalised LVMI, whereas in 50% of resting hypertrophic patients from the L group and in 20% from the HCTZ group a reduction was observed. The ratio between LVMI mean percentage changes and mean percentage changes of SBP and DBP also showed higher values in patients treated with losartan (L group: ⌬%LVMI/⌬% SBP = 0.55, ⌬%LVMI/⌬%DBP = 0.68; HCTZ group: ⌬%LVMI/⌬%SBP = 0.50, ⌬%LVMI/⌬%DBP = 0.48).
The diagnostic procedures were accepted by all patients. The acceptance score ranged from 7 to 9 cm. ABPM had the lowest acceptance, while the ECG and the office BP measurement the highest (Figure 3 ). Side effects related to ABPM were reported by 14 patients (20%), especially linked to pain caused by the inflation of the cuff (nine patients) and to irritation of the skin and/or haematomas under the cuff (five patients). As for nighttime rest, only four patients (6%) reported no sleep at all.
Analysis of variance for different parameters (SBP, DBP, LVMI) showed a significant difference between groups (P Ͻ 0.001) and multiple comparisons showed a significant difference between patients treated with losartan and patients treated with hydrochlorthiazide (P Ͻ 0.05).
The side effects, such as dizziness (4.6% in the L group); headache (2.3% in the L group, 10% in the HCTZ group), asthenia and dry throat (6.6% in the HCTZ group), were light and occurred only at the beginning of the treatment; no patients had cough and adverse laboratory events (Table 2) .
However, by the 10th month, three patients (12%) from the HCTZ group had slightly lower serum potassium values than 3.5 mmoli/l. This finding remained essentially unchanged until the 22nd month, without clinical importance.
Discussion
The effects of losartan on cardiac hypertrophy have been demonstrated in a variety of in vitro and in vivo studies and in models of hypertension, renal disease and stroke. [18] [19] [20] [21] [22] In agreement with a preliminary report, 13,20-22 we found that losartan was able to significantly lower 24 h mean systolic and diastolic BP. Its anti-hypertensive effect was observed not only in the daytime but also at night. This confirms that the anti-hypertensive effect in an od regimen persists over 24 h. 23, 24 No first dose hypotension was observed with losartan. The effect of losartan can be partially related to its active metabolite E-3174, a non-competitive-AT I antagonist with greater potency and longer action than losartan. 25, 26 The acceptance of ABPM was good and without any serious side effects even with the lower acceptance score than other diagnostic procedures. After 22 months, lipidic and glycaemic profiles remained unchanged after the administration of losartan. No patients showed hyperkalaemia or hypouricaemia. Thus, there is a high degree of safety and tolerability which permits use in patients with various pathologies. Two-thirds of adverse reactions during active treatment occurred in the HCTZ group. In the L group, side effects were mostly early and minor. Asthenia and respiratory symptoms, common side effects reported in other losartan-treated patient trials, were not observed in this study. No patients developed angioedema or dry cough, the most important unwanted side effect with ACE inhibitors ( Table 2) .
The capacity of losartan to reduce left ventricular mass and elevated arterial pressure has been observed in animal and human models. 27 The reduction of left ventricular hypertrophy obtained through the use of anti-hypertensive agents is considered another important end-point, as well as reduced BP and quality of life.
Unfortunately, not all anti-hypertensive drugs are equally effective in reversing left ventricular hypertrophy. 6 Several studies confirm the efficacy of losartan on BP. The studies on left ventricular mass are few and not all show an effective reduction of left ventricular hypertrophy by Angiotensin II antagonists (Table 5 ). In our investigation the echocardiography performed after 22 months of treatment, showed a reduction of LVMI in both groups, but only in patients treated with losartan did it reach statistical significance.
The ratio between mean ⌬% of LVMI/mean ⌬% of SBP and DBP showed how the losartan-induced reduction of left ventricular hypertrophy was linked not only to an effect on BP but also to the effect on the renin-angiotensin-aldosterone system, [28] [29] [30] [31] blocking AT-1 receptors and inducing up-regulation of AT-2 receptors that leads to an inhibition of cell proliferation. 32 In conclusion, these data suggest that losartan is able to induce regression of left ventricular hypertrophy. This effect does not seem to be solely dependent on BP reduction, but also on the effect of the drug on the renin-angiotensin system, even if controlled prospective studies will need to evaluate these findings.
